BioSpace News Archive

Equillium, Inc. today announced that on May 31, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 7,200 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan.

Boston Pharmaceuticals today announced new Phase 2a data demonstrating the positive impact of BOS-580, an investigational, long-acting fibroblast growth factor 21 (FGF21) analogue, on the circulating lipidome and changes in the metabolomics advanced steatohepatitis fibrosis (MASEF) score in patients with phenotypic metabolic dysfunction-associated steatohepatitis (MASH).

Envisagenics, an AI-driven revenue generating biotechnology company focused on discovery and development of novel RNA splicing therapeutics, today announced a Series B fundraising round with participation from existing investors Third Kind Venture Capital, Empire State Development and Red Cell Partners, and new strategic investor Bristol Myers Squibb (NYSE: BMY).

AbBC Therapies to Showcase Innovative Approaches to Treating Cancer and Other Diseases at 45th Annual Goldman Sachs Global Healthcare Conference.

Orca Bio today announced that it has completed enrollment in the pivotal Precision-T Phase 3 clinical study.

AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, has announced the expansion of its leadership team with the hiring of Michael D. Krepps, MS, MBA as Head of Corporate Strategy.

SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems, a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, are joining forces to offer a high-volume subcutaneous drug infusion solution.

The Tisch MS Research Center of New York, the world’s largest MS research center, has announced publication of the results of its FDA-approved Phase II stem cell treatment study in a leading stem cell journal, Stem Cell Research & Therapy.

Applied DNA Sciences, Inc. announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 18/302,247, entitled “Compositions and Methods for RNA Synthesis.”

RemeGen Co., Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a commercial-stage biotechnology company, showcased its innovation in the field of global cancer treatment at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) held in Chicago from May 31-June 4, 2024.